7.990USD+0.76%Mkt Cap: 585.43M USDP/E: —Last update: 2026-05-22
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Ph…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap585.43M USD
Enterprise Value435.47M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-38.18M USD
Revenue/Share—
Last Price7.990 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)36.05
PEG—
EV/EBITDA-7.83
EV/Revenue—
P/S—
P/B4.21
EPS (TTM)-1.01
EPS (Forward)0.22
52W Range
4.35074% of range9.270
52W High9.270 USD
52W Low4.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.54%
ROA-30.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.31M USD
CapEx (TTM)587.00K USD
FCF Margin—
FCF Yield-6.47%
Net Debt-145.56M USD
Net Debt/EBITDA2.62
Balance Sheet
Debt/Equity0.94
Current Ratio28.05
Quick Ratio27.63
Book Value/Sh1.884 USD
Cash/Share2.659 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)19.63 USD
Target Range9.000 USD – 29.00 USD
# Analysts8
Ownership
Shares Out.73.27M
Float56.91M
Insiders15.79%
Institutions59.72%
Short Interest
Short Ratio8.9d
Short % Float26.10%
Short % Out.20.04%
Shares Short14.68M
Short (prev mo.)14.82M
Technical
SMA 506.211 (+28.6%)
SMA 2005.661 (+41.1%)
Beta-0.58
S&P 52W Chg28.31%
Avg Vol (30d)2.26M
Avg Vol (10d)2.71M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—